Titre
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Opitz, I.
Auteure/Auteur
Bille, A.
Auteure/Auteur
Dafni, U.
Auteure/Auteur
Nackaerts, K.
Auteure/Auteur
Ampollini, L.
Auteure/Auteur
de Perrot, M.
Auteure/Auteur
Brcic, L.
Auteure/Auteur
Nadal, E.
Auteure/Auteur
Syrigos, K.
Auteure/Auteur
Gray, S.G.
Auteure/Auteur
Aerts, J.
Auteure/Auteur
Curioni-Fontecedro, A.
Auteure/Auteur
Rüschoff, J.H.
Auteure/Auteur
Monkhorst, K.
Auteure/Auteur
Weynand, B.
Auteure/Auteur
Silini, E.M.
Auteure/Auteur
Bavaghar-Zaeimi, F.
Auteure/Auteur
Jakopovic, M.
Auteure/Auteur
Llatjos, R.
Auteure/Auteur
Tsimpoukis, S.
Auteure/Auteur
Finn, S.P.
Auteure/Auteur
von der Thüsen, J.
Auteure/Auteur
Marti, N.
Auteure/Auteur
Dimopoulou, G.
Auteure/Auteur
Kammler, R.
Auteure/Auteur
Peters, S.
Auteure/Auteur
Stahel, R.A.
Auteure/Auteur
Falcoz, P.E.
Auteure/Auteur
Brunelli, A.
Auteure/Auteur
Baas, P.
Auteure/Auteur
Contributrices/contributeurs
Stahel, R.
Hiltbrunner, A.
Kammler, R.
Marti, N.
Ruepp, B.
Dafni, U.
Tsourti, Z.
Zygoura, P.
Vervita, K.
Dimopoulou, G.
Andriakopoulou, C.
Stavrou, A.
Rüschoff, J.H.
Haberecker, M.
Dettwiler, S.
Prutek, F.
Mittmann, C.
Opitz, I.
Vrugt, B.
Friess, M.
Matter, A.
Spichiger-Häusermann, C.
Kirschner, M.B.
Felley-Bosco, E.
Baas, P.
Monkhorst, K.
Nackaerts, K.
Verbeken, E.
Weynand, B.
Nafteux, P.
Moons, J.
Peeters, L.
Ampollini, L.
Tiseo, M.
Silini, E.M.
Gnetti, L.
Carbognani, P.
de Perrot, M.
Bavaghar-Zaeimi, F.
Brcic, L.
Samarzija, M.
Seiwerth, S.
Jakopovic, M.
Nadal, E.
Cardenal, F.
Llatjos, R.
Lorente, S.
Syrigos, K.
Vamvakaris, I.
Tsimpoukis, S.
Boura, P.
Gray, S.G.
Finn, S.P.
Nur, M.M.
Baird, A.M.
Barr, M.P.
Cuffe, S.
Gately, K.
Aerts, J.
Thüsen, J.V.
Bille, A.
Passani, S.
Brunelli, A.
Groupes de travail
ETOP Mesoscape and ESTS Consortia
Liens vers les personnes
Liens vers les unités
ISSN
1556-1380
Statut éditorial
Publié
Date de publication
2023-09
Volume
18
Numéro
9
Première page
1233
Dernière page/numéro d’article
1247
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Pleural mesothelioma (PM) is an aggressive malignancy with increasing prevalence and poor prognosis. Real-life data are a unique approach to reflect the reality of PM epidemiology, treatment, and prognosis in Europe.
A joint analysis of the European Thoracic Oncology Platform Mesoscape and the European Society of Thoracic Surgeons (ESTS) databases was performed to better understand the characteristics and epidemiology of PM, including histologic subtype, staging, and treatment. Overall survival (OS) was assessed, adjusting for parameters of clinical interest.
The analysis included 2766 patients (Mesoscape: 497/10 centers/ESTS: 2269/77 centers). The primary histologic subtype was epithelioid (71%), with 57% patients on stages III to IV. Within Mesoscape, the patients received either multimodality (59%) or palliative intention treatment (41%). The median follow-up was 47.2 months, on the basis of 1103 patients (Mesoscape: 491/ESTS: 612), with 823 deaths, and median OS was 17.4 months. In multivariable analysis, female sex, epithelioid subtype, and lower stage were associated with longer OS, when stratifying by cohort, age, and Eastern Cooperative Oncology Group Performance Status. Within Mesoscape, multimodality treatment including surgery was predictive of longer OS (hazard ratio = 0.56, 95% confidence interval: 0.45-0.69), adjusting for sex, histologic subtype, and Eastern Cooperative Oncology Group Performance Status. Overall, surgical candidates with a macroscopic complete resection had a significantly longer median OS compared with patients with R2 (25.2 m versus 16.4 m; log-rank p < 0.001).
This combined European Thoracic Oncology Platform/ESTS database analysis offers one of the largest databases with detailed clinical and pathologic outcome. Our finding reflects a benefit for selected patients that undergo multimodality treatment, including macroscopic complete resection, and represents a valuable resource to inform the epidemiology and treatment options for individual patients.
A joint analysis of the European Thoracic Oncology Platform Mesoscape and the European Society of Thoracic Surgeons (ESTS) databases was performed to better understand the characteristics and epidemiology of PM, including histologic subtype, staging, and treatment. Overall survival (OS) was assessed, adjusting for parameters of clinical interest.
The analysis included 2766 patients (Mesoscape: 497/10 centers/ESTS: 2269/77 centers). The primary histologic subtype was epithelioid (71%), with 57% patients on stages III to IV. Within Mesoscape, the patients received either multimodality (59%) or palliative intention treatment (41%). The median follow-up was 47.2 months, on the basis of 1103 patients (Mesoscape: 491/ESTS: 612), with 823 deaths, and median OS was 17.4 months. In multivariable analysis, female sex, epithelioid subtype, and lower stage were associated with longer OS, when stratifying by cohort, age, and Eastern Cooperative Oncology Group Performance Status. Within Mesoscape, multimodality treatment including surgery was predictive of longer OS (hazard ratio = 0.56, 95% confidence interval: 0.45-0.69), adjusting for sex, histologic subtype, and Eastern Cooperative Oncology Group Performance Status. Overall, surgical candidates with a macroscopic complete resection had a significantly longer median OS compared with patients with R2 (25.2 m versus 16.4 m; log-rank p < 0.001).
This combined European Thoracic Oncology Platform/ESTS database analysis offers one of the largest databases with detailed clinical and pathologic outcome. Our finding reflects a benefit for selected patients that undergo multimodality treatment, including macroscopic complete resection, and represents a valuable resource to inform the epidemiology and treatment options for individual patients.
PID Serval
serval:BIB_82EE065BEEA5
PMID
Date de création
2023-06-29T13:21:52.674Z
Date de création dans IRIS
2025-05-21T01:07:04Z